Cargando…

Erythroderme Psoriasis nach COVID-19-Erkrankung

We present a clinical case of a patient with acutely exacerbated erythrodermic psoriasis vulgaris after symptomatic infection with SARS-CoV‑2 (severe acute respiratory syndrome coronavirus 2). Various factors are already known that can lead to an exacerbation of psoriasis, such as drugs or infection...

Descripción completa

Detalles Bibliográficos
Autores principales: Demiri, Jeta, Abdo, Miriam, Tsianakas, Athanasios
Formato: Online Artículo Texto
Lenguaje:English
Publicado: Springer Medizin 2021
Materias:
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670040/
https://www.ncbi.nlm.nih.gov/pubmed/34905074
http://dx.doi.org/10.1007/s00105-021-04931-0
_version_ 1784614898770116608
author Demiri, Jeta
Abdo, Miriam
Tsianakas, Athanasios
author_facet Demiri, Jeta
Abdo, Miriam
Tsianakas, Athanasios
author_sort Demiri, Jeta
collection PubMed
description We present a clinical case of a patient with acutely exacerbated erythrodermic psoriasis vulgaris after symptomatic infection with SARS-CoV‑2 (severe acute respiratory syndrome coronavirus 2). Various factors are already known that can lead to an exacerbation of psoriasis, such as drugs or infections with, for example, streptococcus. An association between psoriasis and an infection with SARS-CoV‑2 has been described so far in individual case reports, in which, however, drug treatment with for example hydroxychloroquine, a known trigger of psoriasis, often took place. Later cases of exacerbation of psoriasis, partly as pustular psoriasis have been published also without drug induction. However we present for the first time a case of erythrodermic psoriasis triggered by COVID-19 (coronavirus disease 2019) without an obvious drug trigger.
format Online
Article
Text
id pubmed-8670040
institution National Center for Biotechnology Information
language English
publishDate 2021
publisher Springer Medizin
record_format MEDLINE/PubMed
spelling pubmed-86700402021-12-14 Erythroderme Psoriasis nach COVID-19-Erkrankung Demiri, Jeta Abdo, Miriam Tsianakas, Athanasios Hautarzt Kasuistiken We present a clinical case of a patient with acutely exacerbated erythrodermic psoriasis vulgaris after symptomatic infection with SARS-CoV‑2 (severe acute respiratory syndrome coronavirus 2). Various factors are already known that can lead to an exacerbation of psoriasis, such as drugs or infections with, for example, streptococcus. An association between psoriasis and an infection with SARS-CoV‑2 has been described so far in individual case reports, in which, however, drug treatment with for example hydroxychloroquine, a known trigger of psoriasis, often took place. Later cases of exacerbation of psoriasis, partly as pustular psoriasis have been published also without drug induction. However we present for the first time a case of erythrodermic psoriasis triggered by COVID-19 (coronavirus disease 2019) without an obvious drug trigger. Springer Medizin 2021-12-14 2022 /pmc/articles/PMC8670040/ /pubmed/34905074 http://dx.doi.org/10.1007/s00105-021-04931-0 Text en © The Author(s), under exclusive licence to Springer Medizin Verlag GmbH, ein Teil von Springer Nature 2021 This article is made available via the PMC Open Access Subset for unrestricted research re-use and secondary analysis in any form or by any means with acknowledgement of the original source. These permissions are granted for the duration of the World Health Organization (WHO) declaration of COVID-19 as a global pandemic.
spellingShingle Kasuistiken
Demiri, Jeta
Abdo, Miriam
Tsianakas, Athanasios
Erythroderme Psoriasis nach COVID-19-Erkrankung
title Erythroderme Psoriasis nach COVID-19-Erkrankung
title_full Erythroderme Psoriasis nach COVID-19-Erkrankung
title_fullStr Erythroderme Psoriasis nach COVID-19-Erkrankung
title_full_unstemmed Erythroderme Psoriasis nach COVID-19-Erkrankung
title_short Erythroderme Psoriasis nach COVID-19-Erkrankung
title_sort erythroderme psoriasis nach covid-19-erkrankung
topic Kasuistiken
url https://www.ncbi.nlm.nih.gov/pmc/articles/PMC8670040/
https://www.ncbi.nlm.nih.gov/pubmed/34905074
http://dx.doi.org/10.1007/s00105-021-04931-0
work_keys_str_mv AT demirijeta erythrodermepsoriasisnachcovid19erkrankung
AT abdomiriam erythrodermepsoriasisnachcovid19erkrankung
AT tsianakasathanasios erythrodermepsoriasisnachcovid19erkrankung